Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

ProtoKinetix Q1 2026 Results: Net Loss of $77.7K, Loss Narrows

ProtoKinetix, Inc. is a development stage medical research company that reported a net loss of $77,726 for the quarter ended March 31, 2026, compared to a loss of $97,690 in the prior year period. The company maintains a significant accumulated deficit of $48.7 million and faces substantial doubt about its ability to continue as a going concern due to a lack of revenue and minimal cash reserves.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Net income-0.1-0.1
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: PKTX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ProtoKinetix, Inc.: key numbers

Share price
$0.0020Close, Nov 13
Market cap
$823K
Shares outstanding
411.63MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.